Survival analysis showed that SMYD1 was significantly correlated with RFS in ESCA patients, and with OS and RFS in STAD patients, suggesting that SMYD1 may be a potential tumor marker in these patients. Here, SMYD1 is linked to gastric adenocarcinoma.